SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 755.75+2.5%Nov 21 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (2088)3/29/2017 7:14:55 PM
From: DewDiligence_on_SI  Read Replies (1) of 3559
 
they see limited room for increase drug price down the road, so they initially placed WS price that incorporate allergic asthma indication.
This, too, was covered on the CC. Once asthma is approved, they can raise the effective price by reducing the discounts/rebates when the drug is prescribed for the asthma indication.

Having non-zero discounts/rebates is helpful to a drug manufacturer in the same way that non-zero interest rates are helpful to the Fed: they allow bidirectional wiggle room.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News